# Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine

> **NCT04216888** · PHASE2,PHASE3 · COMPLETED · sponsor: **Dan Iosifescu** · enrollment: 9 (actual)

## Conditions studied

- Depressive Disorder, Treatment-Resistant

## Interventions

- **DRUG:** Ketamine Hydrochloride

## Key facts

- **NCT ID:** NCT04216888
- **Lead sponsor:** Dan Iosifescu
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-26
- **Primary completion:** 2020-12-28
- **Final completion:** 2020-12-28
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2021-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04216888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04216888, "Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04216888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*